Related by context. All words. (Click for frequent words.) 76 Romidepsin 75 Meets Primary Endpoint 74 Cutaneous T 73 Phase 2b Clinical Trial 73 Phase IIb Clinical Trial 73 Phase IIb Trial 72 Oral Fingolimod 72 Prolongs Survival 72 Antitumor Activity 72 Phase 2a Trial 71 Glufosfamide 71 Initiate Clinical Trial 71 Phase III Trial 71 Phase 2b Trial 71 Investigational Treatment 71 Pharmacokinetics PK 71 Improved Survival 71 Long Term Efficacy 71 Patients Treated With 71 Phase 2b Study 70 Previously Treated 70 Sustained Efficacy 70 Study Evaluating 70 SPRYCEL ® 70 Preclinical Data 70 Anti Tumor Activity 70 Patients Receiving 70 NDA Submission 69 Newly Diagnosed Multiple Myeloma 69 AVONEX ® 69 Hsp# Inhibitor 69 II Clinical Trial 69 Omacetaxine 69 Completes Patient Enrollment 69 Immunotherapeutic 69 Interferon beta 1a 69 refractory chronic lymphocytic 69 Myelodysplastic Syndrome MDS 69 Castration Resistant Prostate Cancer 69 Antiviral Activity 69 Relapsing Multiple Sclerosis 69 cell lymphoma CTCL 69 GW# [003] 69 Treated Patients 69 HCV Protease Inhibitor 69 Complicated Skin 69 Fast Track Status 69 Potent Antiviral Activity 69 Adjunctive Therapy 69 Peginterferon 69 Pivotal Phase III 69 Glatiramer Acetate 69 Clinical Trial Results 68 Well Tolerated 68 Single Dose 68 Demonstrates Efficacy 68 Adjuvant Treatment 68 Combination REOLYSIN R 68 FDA Approvals 68 JAK Inhibitor 68 Severe Sepsis 68 Preclinical Study 68 CCX# B 68 Epratuzumab 68 Placebo Controlled Trial 68 familial amyloidotic polyneuropathy FAP 68 Pivotal Study 68 Pivotal Phase II 68 Aflibercept 68 Improves Survival 68 Advanced Melanoma 68 Interferon Gamma 68 ara C 68 dextromethorphan quinidine 68 Investigational Compound 68 Metastatic Melanoma 68 HDAC Inhibitor 68 Presents Preclinical Data 68 Drug Candidate 68 Relapsed Refractory 68 Initiates Clinical Trial 68 Humanized Anti 68 alfa 2a 68 Chronic Lymphocytic Leukemia 68 Demonstrates Positive 68 Confirmatory Phase 68 Granted Orphan Drug 68 Improves Outcomes 68 Pemetrexed 68 Eluting Stent 68 Pooled Analysis 68 Plus Ribavirin 68 Tolerability 68 Trial Evaluating 68 Oral Mucositis 68 IND Application 68 Pivotal Trial 68 Survival Benefit 68 Combination Treatment 67 Files IND 67 alpha 2a 67 Chronic Myelogenous Leukemia 67 Initiates Phase 2b 67 Tyrosine Kinase Inhibitor 67 Initiate Phase 67 romidepsin 67 Initiates Enrollment 67 Receives Orphan Drug Designation 67 Combo Therapy 67 Advanced Renal Cell 67 Albuferon TM 67 Initiated Phase 67 cisplatin gemcitabine 67 Expanded Indication 67 Chronic Myeloid Leukemia 67 Hepatotoxicity 67 Pivotal Trials 67 Significantly Improved 67 Phase IIa Clinical Trial 67 Phase 2a Clinical Trial 67 Novel Oral 67 Metastatic Colorectal Cancer 67 Placebo Controlled Study 67 relapsed MM 67 Autologous Stem Cell Transplantation 67 Bosutinib 67 Diabetic Neuropathy 67 Phase III Clinical Trial 67 Hormone Refractory Prostate Cancer 67 Clinical Efficacy 67 Leukemias 67 Phase Ib Clinical Trial 67 Successfully Completes Phase 67 Previously Untreated 67 See CLINICAL PHARMACOLOGY 67 dasatinib Sprycel ® 67 Tezampanel 67 Advanced Colorectal Cancer 67 Initiates Phase II 67 fosbretabulin 67 Zorbtive TM 67 vinca alkaloid 67 ACTEMRA TM 67 Myeloma Patients 67 Fondaparinux 67 Gemzar ® 67 pan HDAC inhibitor 67 Solid Tumors 67 Demonstrates Significant 67 IL# PE#QQR 67 Shows Efficacy 67 Aliskiren 67 Melphalan 67 PEGASYS ® 67 adalimumab Humira 67 ZACTIMA 67 FDA Accepts 67 Copegus ribavirin 67 ORENCIA ® 67 Ozarelix 67 Panzem R NCD 67 Mycophenolate Mofetil 67 Phase III Trials 66 Investigational Agent 66 Brentuximab Vedotin SGN 66 depsipeptide 66 Anti Tumor 66 Submits NDA 66 docetaxel Taxotere ® 66 leukemia AML 66 Adjuvant Chemotherapy 66 FDA APPROVES 66 Therapeutic Vaccine 66 Eculizumab 66 Syncria R 66 novel histone deacetylase 66 Dose Ranging Study 66 Present Preclinical Data 66 oral prodrug 66 PEG IFN 66 Chronic Hepatitis C 66 Therapeutic Efficacy 66 Treatment Resistant 66 demonstrated antitumor activity 66 antibody MAb 66 Is Well Tolerated 66 essential thrombocythemia ET 66 Pegasys ® 66 Paraplatin ® 66 CIMZIA TM certolizumab pegol 66 Treatment Naive Patients 66 Enzyme Replacement Therapy 66 Unresectable 66 Reports Preclinical Data 66 cetuximab Erbitux R 66 Inhalation Solution 66 Interferon Beta 66 metastatic malignant 66 PKC# 66 Cethromycin 66 Metastatic Renal Cell Carcinoma 66 JAK2 Inhibitor 66 Myelofibrosis 66 HBeAg + 66 First Patient Enrolled 66 lenalidomide Revlimid R 66 thalidomide Thalomid 66 Psoriasis Drug 66 Immunogenicity 66 vapreotide acetate 66 CYT# potent vascular disrupting 66 galiximab 66 Elotuzumab 66 interferon gamma 1b 66 Protease Inhibitor 66 Clolar ® 66 Peginterferon Alfa 2a 66 Platinol ® 66 Mouse Model 66 FOLOTYN ® 66 Demonstrates Sustained 66 Novel Inhibitor 66 Novel Compound 66 Prostate Cancer Vaccine 66 ARIXTRA R 66 Lupus Nephritis 66 beta 1a 66 Novel Mechanism 66 Hypercholesterolemia 66 Immunomodulatory 66 SinuNase TM 66 Hepatic Encephalopathy 66 Pulmonary Arterial Hypertension 66 First Patient Dosed 66 Dose Escalation 66 Demonstrates Potent 66 Navelbine ® 66 Infected Patients 66 Antiangiogenic 66 Schizophrenia Treatment 66 Romiplostim 66 topical gel formulation 66 Cervical Dystonia 66 Elagolix 66 Panzem R 66 HuMax EGFr 65 FOLFOX6 65 bevacizumab Avastin ® 65 Multiple Myeloma Patients 65 Etanercept 65 Presents Positive 65 alpha 2b 65 Efficacy Trial 65 Chronic Sinusitis 65 Aeolus Pharmaceuticals Announces 65 #I TM# 65 Plaque Psoriasis 65 TO AVOID PREGNANCY WHILE 65 CIMZIA TM 65 Investigational Drug 65 Acute Ischemic Stroke 65 Soft Tissue Sarcoma 65 PANVAC VF 65 Sirolimus Eluting Stent 65 monoclonal antibody conjugated 65 Intravenous Formulation 65 Copegus ® 65 FOLFOX6 chemotherapy regimen 65 Paclitaxel Carboplatin 65 IIa Clinical Trial 65 Anticancer Activity 65 orally administered inhibitor 65 Controlled Trial 65 Tiotropium 65 myelodysplastic myeloproliferative diseases 65 metastatic hormone refractory 65 oral beclomethasone dipropionate 65 Diffuse Large B 65 8mg/kg 65 MYCAMINE 65 Clinical Trial Data 65 Sapacitabine 65 melphalan prednisone 65 IN PATIENTS WITH 65 Antigen Specific 65 Pharmacodynamics 65 Initiates Clinical 65 Myelodysplastic Syndromes 65 Polymerase Inhibitor 65 temsirolimus Torisel 65 Telbivudine 65 PEGylated Fab fragment 65 Gout Drug 65 IND Filing 65 Zenvia Phase III 65 Prospective Randomized 65 Patient Enrollment 65 Renal Cell Carcinoma 65 Clinical Trial Evaluating 65 Xanafide 65 Pegylated Interferon 65 cutaneous T 65 Pneumococcal Vaccine 65 PRN FDA Approves 65 novel VDA molecule 65 Initiate Phase III 65 Pegylated Liposomal Doxorubicin 65 5 FU leucovorin 65 R lenalidomide 65 Luteinizing Hormone Releasing Hormone 65 VELCADE melphalan 65 BARACLUDE ® 65 Phase Ib clinical 65 Completes Enrollment 65 Traficet EN 65 MEK Inhibitor 65 Capecitabine 65 FDA Okays 65 Chronic Hepatitis B 65 leukemia CLL 65 erlotinib Tarceva ® 65 Nebulized 65 relapsing multiple sclerosis 65 Cell Lymphoma 65 huN# DM1 65 Rheumatoid Arthritis Drug 65 Initiates Phase III 65 HER2 Positive Breast Cancer 65 PEG SN# 65 Relapsed Refractory Multiple Myeloma 65 INSPIRE Trial Phase III 65 KRN# 65 RAPTIVA 65 hypereosinophilic syndrome 65 Irinotecan 65 Multiple Ascending Dose 65 Initiate Phase II 65 Elderly Patients 65 Acute Attacks 65 Prophylactic Treatment 65 LymphoStat B TM 65 Posaconazole 65 Carfilzomib 65 Investigational Oral 65 evaluating tivozanib 65 Cypher Sirolimus 65 Interferon Alfa 65 Shows Promise Against 65 Percutaneous Tibial Nerve Stimulation 65 bevacizumab Avastin R 65 Pharmacokinetic Study 65 Personalized Immunotherapy 65 Refractory Hodgkin Lymphoma 65 Archexin 65 Orally Active 65 Nilotinib 65 Novel Therapeutic 65 AVASTIN 65 Teva Provides Update 65 Mitoxantrone 65 Disease Progression 65 Chemophase 65 receptor tyrosine kinase inhibitor 65 Bezielle 65 Transdermal Patch 65 Statistically Significant 65 Ridaforolimus 65 CRLX# 65 acetonide FA 65 Rotavirus Vaccine 65 plus DOXIL 64 G#DT 64 Therapy Evaluation 64 ribavirin RBV 64 hormone refractory metastatic prostate 64 Decitabine 64 vinorelbine tartrate 64 Pivotal Phase 64 relapsed refractory multiple myeloma 64 5 fluorouracil leucovorin 64 Pegylated 64 Advanced Prostate Cancer 64 Milestone Payment 64 Double Blind Randomized 64 Fulvestrant 64 HQK 64 CLL SLL 64 Drug Shows Promise 64 Receives Orphan Drug 64 DAVANAT 64 Intravitreal 64 Vicriviroc 64 R Saizen R 64 Therapy Improves 64 Aryplase 64 TNF Blockers 64 alefacept 64 Preclinical Models 64 Colorectal Cancer Patients 64 PEGINTRON TM 64 phase IIIb 64 sunitinib Sutent 64 Voreloxin 64 Significantly Improves 64 catheter occlusion 64 Platelet Inhibition 64 RNAi Therapeutics 64 Severe Asthma 64 Kidney Transplant Patients 64 Diabetic Macular Edema DME 64 lexidronam injection 64 Quinamed 64 AAG geldanamycin analog 64 Overactive Bladder 64 2 methoxyestradiol 64 Pegloticase 64 Vaccine Adjuvant 64 Anticancer Drug 64 Patients Treated 64 Antitumor activity 64 Pazopanib 64 Safinamide 64 Receives Approvable Letter 64 Patients Suffering 64 Cimzia certolizumab pegol 64 Fungal Infections 64 Kinase Inhibitor 64 Naive Patients 64 Hepatocellular Carcinoma 64 Maribavir 64 GOUT 64 Renal Impairment 64 chronic eosinophilic leukemia 64 pan histone deacetylase 64 bortezomib Velcade R 64 Cardiotoxicity 64 Relapsing Remitting Multiple Sclerosis 64 CIMZIA ™ 64 Rheumatoid Arthritis Patients 64 Degarelix 64 PROSTVAC VF 64 orally inhaled migraine 64 Pediatric Patients 64 Triapine 64 Diabetic Patients 64 Anticancer Drugs 64 sunitinib malate 64 FDA Approvable Letter 64 Treatment Naive HIV 64 Diabetic Macular Edema 64 Advanced Solid Tumors 64 ThermoDox R 64 Schizophrenia Drug 64 colesevelam HCl 64 Fludarabine 64 Controlled Study 64 Study Showed 64 T Cell Lymphoma 64 Demonstrates Potential 64 FASLODEX 64 RNAi Therapeutic 64 TAXOTERE R 64 Phase III Pivotal 64 Neoadjuvant 64 Daclizumab 64 recurrent glioblastoma multiforme 64 Bronchodilator 64 Ecallantide 64 Golimumab 64 Receives Fast Track 64 Blinatumomab 64 Aurora Kinase 64 Heterozygous Familial Hypercholesterolemia 64 TLK# 64 Relapsed Multiple Myeloma 64 FUSILEV enhances 64 Phase #b/#a clinical 64 Systemic Sclerosis 64 Treatment Regimen 64 Efficacy Results 64 Randomized Clinical Trial 64 HCV Genotype 64 Cloretazine ® 64 EXPAREL TM 64 Clinical Outcome 64 brivaracetam 64 Lupus Drug 64 Pivotal Clinical Trial 64 Tumor Response 64 omacetaxine mepesuccinate 64 docetaxel Taxotere R 64 Subgroup Analysis 64 Double Blind Placebo 64 targeting CD# 64 Bortezomib 64 Hepatitis C Treatment 64 Fludara ® 64 Cyclophosphamide 64 Follicular Lymphoma 64 Dose Escalation Study 64 Protease Inhibitors 64 Renal Cancer 64 Xeloda ® 64 PNP inhibitor 64 MAGE A3 ASCI 64 IMiDs ® compound 64 Toxicities 64 Parathyroid Hormone 64 2 inhibitor CYT# 64 Fingolimod 64 Simulect 64 DUROS 64 Vidaza azacitidine 64 cetuximab Erbitux ® 64 Lubiprostone 64 lymphoid malignancies 63 Inhaled Corticosteroids 63 Zenvia ™ 63 Darinaparsin 63 MyVax R 63 oncolytic virus therapies 63 etanercept Enbrel 63 Mantle Cell Lymphoma 63 Cloretazine 63 sorafenib Nexavar 63 Dual Opioid 63 Diabetic Foot Ulcer 63 certolizumab 63 metastatic colorectal 63 Dupuytren Contracture 63 R Bortezomib 63 Aplidin R 63 Acute Heart Failure 63 Phase 1b trial 63 TELINTRA 63 rilonacept 63 Pertuzumab 63 Androxal TM 63 RE MODEL 63 Metastatic Pancreatic Cancer 63 Myelodysplastic Syndrome 63 Inhalation Aerosol 63 Monotherapy 63 Progenitor Cells 63 Randomized Double blind 63 Biomarker Study 63 adefovir dipivoxil 63 Replacement Therapy 63 Treatment Experienced 63 5 Fluorouracil 63 Randomized Clinical Trials 63 metastatic pancreatic 63 advanced hepatocellular carcinoma 63 Amgen Neulasta R 63 PEGylated interferon beta 1a 63 dual endothelin receptor antagonist 63 YONDELIS 63 Onyx Pharmaceuticals Announces 63 Vandetanib 63 transthyretin TTR mediated amyloidosis 63 ® decitabine 63 PDX pralatrexate 63 Knee Osteoarthritis 63 Phase 1b clinical trials 63 Plecanatide 63 Septic Shock 63 Lenocta 63 Nucleoside 63 sorafenib tablets 63 Enzastaurin 63 gefitinib Iressa 63 histone deacetylase HDAC inhibitor 63 Unfractionated Heparin 63 Solazed ™ 63 Chronic Heart Failure 63 sunitinib Sutent ® 63 Develop Novel 63 haematologic malignancies 63 Partial Onset Seizures 63 Talactoferrin 63 non nucleoside inhibitor 63 imatinib Gleevec ® 63 Randomized Double Blind 63 Systemic Delivery 63 Demonstrated Significant 63 Oral Cladribine 63 Hepatitis C Genotype 63 Proxinium TM 63 Showed Significant 63 Recombinant Human 63 Node Positive 63 Dalbavancin 63 trastuzumab DM1 T DM1 63 STELARA TM 63 dasatinib Sprycel 63 irinotecan doxorubicin oxaliplatin paclitaxel 63 pharmacokinetic PK study 63 Liprotamase 63 Initiates Phase 63 PRTX 63 SYN# 63 Milestone Payments 63 Xcytrin R 63 metastatic GIST 63 Pafuramidine 63 sodium thiosulfate STS 63 INCB# [003] 63 Noxafil 63 prokinetic agent 63 Philadelphia Chromosome Positive 63 relapsed multiple myeloma 63 Treatment Naïve 63 Universal Flu Vaccine 63 somatostatin analog 63 PegIFN 63 Factor VIIa 63 Lenalidomide 63 Carbidopa Levodopa 63 Adefovir 63 Metastatic Prostate Cancer 63 Tesetaxel 63 ALN TTR 63 Achieves Primary Endpoint 63 Angiotensin Converting Enzyme 63 STELARA ® 63 biologic DMARD 63 erlotinib Tarceva R 63 Confirms Efficacy 63 Advanced Pancreatic Cancer 63 Valopicitabine 63 ceftazidime 63 Skeletal Muscle 63 ORENCIA R 63 Sipuleucel T 63 refractory cutaneous T 63 ribavirin Copegus ® 63 Arno Therapeutics 63 GVAX ® 63 Tipranavir 63 Denufosol 63 basiliximab 63 Dual Antiplatelet Therapy 63 Interferon alfa 63 ritonavir boosted 63 Diabetic Nephropathy 63 Tanespimycin 63 Oncolytic 63 Adenoviral 63 non splenectomized 63 Radioimmunotherapy 63 Seliciclib 63 liposome injection 63 Cell Transplants 63 Phase III Pivotal Trial 63 FS Antihemophilic Factor Recombinant 63 virus HCV protease inhibitor 63 Files Investigational 63 NICE Recommends 63 Intranasal 63 Orphan Status 63 trastuzumab Herceptin R 63 EOquin TM 63 Metabolic Disorder 63 pediatric Crohn disease 63 stage IIIb IV 63 Tyrosine Kinase Inhibitors 63 Zarnestra 63 Amrubicin 63 ST Segment Elevation 63 TNF Tumor Necrosis Factor 63 humanized monoclonal 63 Phase 1a clinical 63 Randomized Phase II 63 topically applied SEPA 63 fludarabine cyclophosphamide 63 First Patient Treated 63 Preclinical Efficacy 63 MabCampath 63 Monoclonal Antibody 63 Vitrasert R 63 AEGR 63 arsenic trioxide injection 63 atypical Hemolytic Uremic Syndrome 63 PEGylated anti 63 Doxil ® 63 Cell Lymphoma CTCL 63 RELOVAIR ™ 63 Moxifloxacin 63 Oral Insulin 63 Disease Modifying 63 Malignant Melanoma 63 Cerebril TM 63 mapatumumab 63 Integrase Inhibitor 63 blinded randomized placebo controlled 63 Peginterferon alfa 2b 63 E1 INT TM 63 Nitazoxanide 63 huC# DM4 63 Atypical Antipsychotic 63 preclinical efficacy 63 dependent kinase inhibitor 63 alemtuzumab Campath 63 AA Amyloidosis 63 Shows Promising 63 cell carcinoma RCC 62 Vildagliptin 62 Topline Results 62 CANCIDAS 62 Subtypes 62 saline placebo 62 ALN HPN 62 Systemic Lupus Erythematosus SLE 62 plus prednisone 62 Adverse Event 62 investigational immunotherapy 62 TRO# 62 intranasal formulation 62 Chronic Renal Failure 62 paclitaxel Taxol R 62 LEUKINE 62 Abiraterone Acetate 62 diarrhea predominant irritable 62 Tumor Necrosis Factor 62 Combination Therapy 62 refractory metastatic 62 Newly Diagnosed 62 Solazed TM 62 triciribine phosphate monohydrate 62 Chronic Lymphocytic Leukemia CLL 62 systemic anaplastic large 62 Interferon Alpha 62 LymphoStat B belimumab 62 standard chemotherapy regimen 62 Phase 2a Study 62 Vascular Disrupting Agent 62 Mg Uk 62 Epidermal Growth Factor Receptor 62 atazanavir sulfate 62 Targeted Therapy 62 JAK2 inhibitor 62 Treating Chronic 62 Adalimumab 62 BARACLUDE R 62 CEQ# 62 forodesine 62 mertansine 62 Injection Site 62 severe oral mucositis 62 Phase 1b Clinical Trial 62 EGFR HER2 62 imatinib resistant 62 Rotigotine 62 follicular Non Hodgkin 62 Tumor Targeting 62 Randomised 62 dacarbazine DTIC 62 Spectrum Pharmaceuticals Announces 62 constipation OIC 62 SNT-MC#/idebenone 62 Renal Cell Carcinoma RCC 62 Ofatumumab 62 metastatic colorectal carcinoma 62 Newly Diagnosed Patients 62 miconazole Lauriad ® 62 AIR CF1 62 pegylated interferon alfa 2a 62 ® bortezomib 62 Ocrelizumab 62 topically administered 62 Tuberculosis Vaccine 62 Phase III Clinical Trials 62 Treatment Shows Promise 62 Phase IIA 62 Dacogen injection 62 IV Busulfex 62 Androgen Deprivation Therapy 62 Dose Response 62 Teriflunomide 62 Liposomal 62 cancer mCRC 62 HP Acthar Gel repository 62 Squalamine 62 gemcitabine carboplatin 62 B Cell Lymphoma 62 papillary renal cell carcinoma 62 oral ridaforolimus 62 Clofarabine 62 Vidofludimus 62 Lung Cancer Trial 62 erythematosus SLE 62 Tablet Formulation 62 Begins Dosing 62 peginterferon alpha 2a 62 allogeneic hematopoietic stem cell 62 Amgen Neulasta ® 62 Ceflatonin R 62 novel emulsion formulation 62 Dyloject TM 62 haematological malignancies 62 Therapeutic Antibody 62 Vitaxin 62 Iluvien TM 62 Gastric Cancer 62 Receives Milestone Payment 62 Recurrent Glioblastoma 62 Bevacizumab 62 refractory gout 62 ® lenalidomide 62 SAR# [004] 62 Mylan Receives Approval 62 substantially excreted 62 UPLYSO 62 IMiDs ® 62 Demonstrate Significant 62 Antitumor 62 HER2 Positive 62 Glatiramer acetate 62 Neoadjuvant Chemotherapy 62 Orally administered 62 Doripenem 62 vidofludimus 62 RECIST Response Evaluation Criteria 62 Low Dose 62 azacytidine 62 Potent Inhibitor 62 Novel Antibiotic 62 personalized cellular immunotherapy 62 metastatic castration resistant 62 Forodesine HCl 62 Tarceva TM 62 CD# CEA 62 Dacogen decitabine 62 Receives Complete Response 62 Sudhir Agrawal D.Phil 62 Blood Pressure Drug 62 Gemcitabine 62 hyperphenylalaninemia HPA due 62 Taro Receives 62 rxRNA 62 Glioblastoma Multiforme 62 Hematological Cancers 62 Cytotoxic 62 Receives Positive Opinion 62 Taxotere ® 62 CTAP# Capsules 62 delivers fluocinolone acetonide FA 62 Fluorouracil 62 Bipolar Depression 62 Randomized Study 62 Inflammatory Markers 62 stage IIIB 62 Hedgehog Pathway Inhibitor 62 By JENNIFER LEARN 62 paclitaxel Taxol ® 62 Tesmilifene 62 Immunosuppressant 62 Afatinib 62 CALGB # [002] 62 Crit Rev 62 Entereg R 62 Alocrest 62 Catena ® 62 Angioedema 62 Cloretazine R VNP#M 62 SinuNase ™ 62 Supplemental Biologics License Application 62 Generalized Anxiety Disorder 62 unfractionated heparin UFH 62 Orphan Designation 62 Invasive Fungal Infections 62 CINTREDEKIN BESUDOTOX 62 Treatment Naïve Patients 62 Campath alemtuzumab 62 velafermin 62 Atypical Hemolytic Uremic Syndrome 62 Azacitidine 62 Vidaza ® 62 capecitabine Xeloda 62 Placebo Controlled 62 4mg/kg 62 Aztreonam Lysine 62 DDP# 62 Vaccine Candidate 62 MELAS 62 investigational humanized monoclonal antibody 62 Radiofrequency Ablation RFA 62 lymphoma CTCL 62 pain palliation 62 JAK inhibitor 62 Migraine Drug 62 Kahalalide F 62 methylnaltrexone bromide 62 hypoxia activated prodrug 62 plus dexamethasone 62 BRIM2 62 generation purine nucleoside 62 pralatrexate injection folate analogue 62 PHASE III 62 Positive Opinion 62 candesartan cilexetil 62 Nicotine Vaccine 62 PF # [002] 62 Acute Decompensated Heart Failure 62 post herpetic neuralgia PHN 62 zonisamide SR 62 FOR FURTHER INFORMATION ABOUT 62 herpetic keratitis 62 Neuroendocrine Tumors 62 Tolvaptan 62 DEB# 62 abacavir Ziagen 62 Heart Failure Patients 62 Emerging Therapies 62 Drug Resistant 62 selective modulator 62 essential thrombocythemia 62 TYKERB 62 refractory CLL 62 Anticoagulant 62 FUSILEV ® 62 advanced metastatic renal 62 Fibrillex TM 62 Chemotherapy Induced 62 Resistant Hypertension 62 mGluR5 NAM 62 TRANSDUR ® 62 Xelox 62 C1 Inhibitor 62 DermaVir Patch 62 Sevelamer 62 alemtuzumab MS 62 Tigecycline 62 Lanthanum Carbonate 62 Inflammatory Arthritis 62 denileukin diftitox 62 Fewer Side Effects 62 CHARM Added 62 Paroxysmal Nocturnal Hemoglobinuria PNH 62 treatment naive genotype 62 Vicinium TM 62 Initiates Dosing 61 Darunavir 61 See WARNINGS 61 Randomized Double Blind Placebo 61 CA4P 61 Drug Fails 61 cyclophosphamide methotrexate 61 Anthracycline 61 Raptiva ® 61 elotuzumab 61 phase III isavuconazole 61 dose melphalan 61 Phase IIIb 61 Chemoradiation 61 Engerix B 61 developing Bicifadine serotonin 61 Phase Ib II 61 Idiopathic Pulmonary Fibrosis 61 somatostatin analogue 61 posaconazole 61 ISTODAX 61 Commence Phase 61 INC# 61 inhibitor RG# 61 Cholesterol Lowering Drug 61 Randomized Phase 61 Dyskinesia 61 Allogeneic 61 GAMMAGARD 61 PRT# 61 Immunosuppression 61 Atopic Dermatitis 61 NASH Huntington 61 Onconase 61 ZEVALIN ® 61 erythematosus 61 GRNVAC1 61 oral nucleoside analogue 61 Refractory Angina 61 Small Molecule 61 BiTE Antibody 61 Significantly Reduces 61 toenail onychomycosis 61 Ranibizumab 61 uricase 61 Li Fraumeni Syndrome 61 receiving INTRON 61 COPEGUS R 61 plus prednisone prednisolone 61 Acute Coronary Syndromes ACS 61 metastatic neuroendocrine tumors 61 Lenocta TM 61 Chronic Myeloid Leukemia CML 61 Treatment Outcome 61 FEMALES SHOULD BE ADVISED 61 Attenuates 61 Receptor Agonist 61 PEG INTRON R